ScreenerHero

VOR Vor Biopharma Inc.

NAS · US · Healthcare · Biotechnology · vorbio.com
18.78USD+2.57%Mkt Cap: 1.02B $P/E: 0.10

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.02B USD
Enterprise Value620.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-695.98M USD
Revenue/Share—
Last Price18.78 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.10
P/E (Forward)-4.80
PEG—
EV/EBITDA-5.29
EV/Revenue—
P/S—
P/B-4.98
EPS (TTM)180.18
EPS (Forward)-3.82
52W Range
6.50028% of range49.95
52W High49.95 USD
52W Low6.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE423.57%
ROA-149.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-142.71M USD
CapEx (TTM)941.00K USD
FCF Margin—
FCF Yield-7.81%
Net Debt-463.25M USD
Net Debt/EBITDA3.95
Balance Sheet
Debt/Equity-0.02
Current Ratio19.15
Quick Ratio18.79
Book Value/Sh-3.68 USD
Cash/Share7.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateSep 19, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.00 USD
Upside (mean)+107.7%
Target Range27.00 USD – 50.00 USD
27.00+107.7% to mean50.00
# Analysts8
Ownership
Shares Out.54.19M
Float37.23M
Insiders9.26%
Institutions86.84%
Short Interest
Short Ratio10.8d
Short % Float15.72%
Short % Out.13.36%
Shares Short7.90M
Short (prev mo.)7.35M
Technical
SMA 5021.96 (-14.5%)
SMA 20016.78 (+11.9%)
Beta1.78
S&P 52W Chg16.45%
Avg Vol (30d)1.02M
Avg Vol (10d)1.38M
Technical Indicators
RSI (14)40.9
MACD-1.0283
MACD Signal-0.8141
MACD Hist.-0.2142
BB Upper25.39 USD
BB Middle20.56 USD
BB Lower15.74 USD
BB Width46.92%
ATR (14)1.314 USD
Vol Ratio (20d)0.46x